Incyte Corporation (INCY): Price and Financial Metrics


Incyte Corporation (INCY)

Today's Latest Price: $95.08 USD

4.31 (-4.34%)

Updated Jan 27 1:28pm

Add INCY to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 485 in Biotech

See all "A" rated Strong Buy stocks

INCY Stock Summary

  • INCY has a market capitalization of $21,766,021,385 -- more than approximately 89.86% of US stocks.
  • Of note is the ratio of Incyte Corp's sales and general administrative expense to its total operating expenses; only 9.08% of US stocks have a lower such ratio.
  • For INCY, its debt to operating expenses ratio is greater than that reported by merely 5.57% of US equities we're observing.
  • If you're looking for stocks that are quantitatively similar to Incyte Corp, a group of peers worth examining would be VIR, BNTX, BGNE, SRPT, and NTLA.
  • Visit INCY's SEC page to see the company's official filings. To visit the company's web site, go to www.incyte.com.

INCY Stock Price Chart Interactive Chart >

Price chart for INCY

INCY Price/Volume Stats

Current price $95.08 52-week high $110.36
Prev. close $99.39 52-week low $62.48
Day low $94.88 Volume 536,868
Day high $99.38 Avg. volume 1,151,032
50-day MA $87.29 Dividend yield N/A
200-day MA $93.51 Market Cap 20.82B

Incyte Corporation (INCY) Company Bio


Incyte Corporation focuses on the discovery, development, and commercialization of proprietary therapeutics in oncology in the United States and internationally. The company was founded in 1991 and is based in Wilmington, Delaware.


INCY Latest News Stream


Event/Time News Detail
Loading, please wait...

INCY Latest Social Stream


Loading social stream, please wait...

View Full INCY Social Stream

Latest INCY News From Around the Web

Below are the latest news stories about Incyte Corp that investors may wish to consider to help them evaluate INCY as an investment opportunity.

Incyte's (INCY) BLA for Cancer Drug Accepted for Priority Review

Incyte's (INCY) application for pipeline candidate, retifanlimab, for adult patients with locally advanced or metastatic squamous cell carcinoma of the anal canal (SCAC) gets Priority Review.

Yahoo | January 22, 2021

Mizuho Securities Stick to Their Hold Rating for Incyte Corp By Investing.com

Mizuho Securities Stick to Their Hold Rating for Incyte Corp

Investing.com | January 21, 2021

Incyte Announces Acceptance and Priority Review of BLA for Retifanlimab as a Potential Treatment for Patients with Squamous Cell Carcinoma of the Anal Canal (SCAC)

WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY--Incyte Announces Acceptance and Priority Review of BLA for Retifanlimab as a Potential Treatment for Squamous Cell Carcinoma of the Anal Canal (SCAC)

Business Wire | January 21, 2021

Incyte to Report Fourth Quarter and Year-End 2020 Financial Results

WILMINGTON, Del.--(BUSINESS WIRE)--Incyte (Nasdaq:INCY) announced today that it has scheduled its fourth quarter and year-end 2020 financial results conference call and webcast for 8:00 a.m. ET on Tuesday, February 9, 2021. The schedule for the press release and conference call/webcast is as follows: • Q4 & YE 2020 Press Release: February 9, 2021 at 7:00 a.m. ET • Q4 & YE 2020 Conference Call: February 9, 2021 at 8:00 a.m. ET • Domestic Dial-In Number: 877-407-3042 • International Dial-

Business Wire | January 19, 2021

RBC Capital Stick to Their Hold Rating for Incyte Corp By Investing.com

RBC Capital Stick to Their Hold Rating for Incyte Corp

Investing.com | January 14, 2021

Read More 'INCY' Stories Here

INCY Price Returns

1-mo 10.12%
3-mo 9.26%
6-mo -3.73%
1-year 24.35%
3-year -0.45%
5-year 34.75%
YTD 9.31%
2020 -0.39%
2019 37.32%
2018 -32.86%
2017 -5.55%
2016 -7.54%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.905 seconds.